Shionogi is a Japanese based large pharmaceutical company specialising in the manufacture and distribution of pharmaceuticals, diagnostic reagents and medical devices.
Pain, metabolic and infectious diseases are the three cores therapeutic focuses of the company’s medical activities. In addition to these indications Shionogi’s diagnostic division focuses on treatments for cardiovascular diseases and allergies. The company is also starting to branch out into new areas of unmet medical need such as women’s health.
Shionogi was put together back in 1878 and it started manufacturing chemicals in 1892, it became officially incorporated in 1919. Over the past 100 years it has expanded all over the world and set up strategic bases; Shionogi has also been involved with some major big pharma companies; developing a joint venture with GlaxoSmithkline in 2001 and going on to sign a marketing agreement with AstraZeneca for its blockbuster product Crestor.
In 1992 Shionogi began to crack the US market by acquiring Eli Lilly’s capsule business, this established Shionogi Qualicaps. Shionogi USA was formed following this to collectively deal with all the American work being carried out. In 2008 Shionogi acquired Sciele Pharma and from this deal in 2010 Shionogi Inc was created to combine all the companies and associated activities. Shionogi Inc. Is a very active company to date and is regularly involved with licensing and marketing deals.
Naturally Shionogi & Co., Ltd is based in Tokyo; from its several other subsidiaries, five are located within Japan and six are located outside of Japan. The global companies include the afore mentioned Shinogi Inc and Ezose Sciences which are both based in New Jersey, USA, the development company Shionogi Limited which can be found in London and finally three other companies that are based in Taiwan, Hong Kong and Shanghai.
Shionogi’s expansion around the world allows it to access new innovations and strengthen its own development capabilities by soaking in and using the local environment; For example in the US, the company has concentrated on further developing its pain related medications but it is also using its location to take full advantage of regional licensing opportunities in new unmet medical areas such as women’s health. In the UK, Shionogi has set up a development Center which promotes the SHIONOGI Science Program, a joint research collaboration project that works alongside academic institutions to develop research and commercialize pipeline products. This Center is positioned perfectly to then launch these products in and around Europe.
Shionogi has recognized the need to partner with other companies in order to license, acquire and develop new products. The company has a very healthy partnering history, signing many licensing deals with companies such as Enanta, Peninsula Pharmaceuticals and very recently UK based Mundipharma. This latest deal is a licensing deal for exclusive rights to develop, manufacture and commercialize OxyContin tablets for the treatment of pain. Since 2005 he company has signed over 30 partnering deals.
Part of Shionogi’s plans moving forwards is to develop and distribute globally, this will no doubt include many more partnerships. Key areas of interest are pain, infectious and metabolic diseases.
Shionogi is often present at a large number of partnering events throughout the year.
Partnering events are a great place to meet lots of potential partners face to face in a short space of time.
Events with Shionogi presence include but are not limited to:
- BIO International Convention and Business Forum
- BioEurope / BioEurope Spring
For a full list of forthcoming partnering events where you could meet with Shionogi in person visit Current Partnering’s Event calendar.
Contacting Shionogi for partnering
Shionogi can be contacted in relation to partnering through a number of channels. Here is a list of the most common channels:
Partnering events: face to face contact is generally considered the most effective form of contact. Partnering events not only allow face to face contact but also contact with multiple companies for the price of one flight and hotel reservation. This benefit makes partnering events the most cost effective method of making personal introductions as a start point for partnering discussions.
See Current Partnering’s event calendar for details of forthcoming events.
Direct contact: there are several sources of direct contact with Shionogi Kabi’s business development team
- Phone: Picking up the phone and speaking with an individual is the best form of non-face to face contact as it allows your name and voice to be remembered and associated with an opportunity.
- Email: Sending an email is another good way of making contact. Ideally, research the individual responsible for the therapy/technology area being targeted and get in touch. Email contact to a named individual view the list of contacts at Shionogi’ website for details.
- LinkedIn: Business to business contact is increasingly taking place via LinkedIn, the global online networking channel.
Many of Shionogi’s business development executives have LinkedIn profiles and can be found by viewing the company’s profile. Visit Shionogi LinkedIn page here.
Opportunity submission form: the least favourable channel but worth using if you do not have access to the other channels mentioned above.
Available reports from Current Partnering
Report: Partnering Deals and Alliances with Shionogi
Available resources for deal coverage for Shionogi
Read: more on Shionogi company profile, recent partnering, M&A and financing news and articles
Report: Practical Guide to Finding Partners
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk